Life 4 Liam & Friends

Mission to support families who are impacted by NPC and help find a cure through connecting NPC families, spreading awareness, and supporting medical research.

[Life 4 Liam & Friends @Life4Liam]

Our fight for Liam and others with Niemann-Pick Type C is at risk due to proposed $18B NIH cuts. Research is our hope for a cure. Read our story and join us to advocate for funding! #NPC #RareDisease #SaveResearch

https://t.co/Nq1A8N53O0

[Life 4 Liam & Friends @Life4Liam]

https://t.co/UWfwB8lzdF

[Life 4 Liam & Friends @Life4Liam]

CRISPR Gene Editing Trial for Primary Hyperoxaluria Type 1 (PH1)

Arbor Biotechnologies dosed the first patient in their CRISPR trial for PH1 at Mayo Clinic. Well-tolerated so far—this metabolic gene edit could inform NPC therapies. Let’s keep pushing for cures! #RareDisease #CRISPR #NPC

[Life 4 Liam & Friends @Life4Liam]

https://t.co/EXHi4fvnf1

[Life 4 Liam & Friends @Life4Liam]

Prime Editing for Chronic Granulomatous Disease (CGD)

Prime Editing restored 66% immune function in a CGD patient—3x above curative threshold. Insights like this could inspire treatments for lysosomal disorders like NPC. Hope for rare diseases! #RareDisease #GeneTherapy #NPC

[Penn Engineering @PennEngineers]

Fewer side-effects, more effectiveness. @MJMitchell_Lab's lab redesigned mRNA lipid nanoparticles using olive oil-inspired chemistry. Adding phenol groups reduces inflammation, making mRNA therapies safer & more effective. "It's a win-win," says Mitchell.

[Life 4 Liam & Friends @Life4Liam]

🔗 https://t.co/orluaQsRCf

[Life 4 Liam & Friends @Life4Liam]

Prime Editing News

Major leap for gene editing in the brain! New research shows Prime Editing successfully corrected mutations causing a rare neurological disease in mice. This is a first & a huge proof-of-concept. Offers incredible hope for developing brain-targeted therapies for #NiemannPick Type C.

#GeneTherapy #RareDisease #PrimeEditing

[Life 4 Liam & Friends @Life4Liam]

5. Future Directions with AI and Multi-Omics: Integrating MS lipidomics with other omics (e.g., proteomics, metabolomics) and leveraging artificial intelligence can uncover complex molecular interactions in NPC. This multi-omics approach, as suggested in the review, could lead to novel therapeutic targets and precision medicine strategies by modeling disease pathways more accurately.

By providing robust tools for diagnosis, deepening pathophysiological insights, and supporting therapeutic development, MS lipidomics accelerates NPC research, paving the way for improved clinical management and potential cures for this rare neurodegenerative disease.

[Life 4 Liam & Friends @Life4Liam]

Exciting new review on advancing mass spectrometry in lipidomics for Niemann-Pick type C (NPC) disease! Explores MS tools, biomarkers like oxysterols & sphingolipids, and future integration with AI & omics for better diagnosis & therapies. A must-read for rare disease research!

[Life 4 Liam & Friends @Life4Liam]

4. Advanced MS Techniques: The review highlights cutting-edge MS platforms (e.g., Q-TOF, Orbitrap, MALDI-TOF) and techniques like shotgun lipidomics and LC-MS, which offer high sensitivity, specificity, and resolution. These tools allow comprehensive lipidome analysis, detecting hundreds to thousands of lipid species, unlike traditional methods that focus on single lipids, thus providing a holistic view of NPC’s lipid alterations.

[Life 4 Liam & Friends @Life4Liam]

https://t.co/1G5yEBENsl

[Life 4 Liam & Friends @Life4Liam]

Azafaros’ Phase 3 NAVIGATE Trial Initiation

Azafaros doses 1st patient in Phase 3 NAVIGATE trial for nizubaglustat in NPC & GM1/GM2 gangliosidoses. Key step for lysosomal storage disorder research! Could inform gene therapy strategies.

#NPC #RareDisease #GeneTherapy

[Life 4 Liam & Friends @Life4Liam]

https://t.co/zlRczwdG2C

[Life 4 Liam & Friends @Life4Liam]

FDA Regulatory Shift
Key regulatory news for the #RareDisease community. The FDA is signaling more flexibility on accelerated approval for gene therapies, potentially making it the "norm". Using surrogate endpoints in small trials could significantly shorten the path from lab to clinic for #NiemannPick therapies. #FDA #GeneTherapy #DrugDevelopment

[Life 4 Liam & Friends @Life4Liam]

Good news for the NPC community in Europe!

The European Medicines Agency (EMA) has recommended granting marketing authorization for Aqneursa (levacetylleucine) for the treatment of neurological manifestations of NPC in adults and children aged six years and older and weighing at least 20 kg.

While not a gene therapy, this oral medication aims to improve neurological signs, symptoms, and functioning by targeting underlying processes of neurological dysfunction, specifically correcting energy metabolism and improving ATP production in cerebellar tissues.

This is a significant step, as currently, miglustat is the only authorized medicine for NPC, and Aqneursa offers an additional therapeutic avenue. The recommendation will now be sent to the European Commission for final approval.

New treatment for Niemann-Pick type C disease | European Medicines Agency (EMA) https://t.co/vM9MfvGP4j